REPOTRECTINIB vs REVUMENIB: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
REPOTRECTINIB vs REVUMENIB: Safety Overview
| Metric | REPOTRECTINIB | REVUMENIB |
|---|---|---|
| Total FAERS Reports | 187 | 371 |
| Deaths Reported | 27 | 49 |
| Death Rate | 14.4% | 13.2% |
| Hospitalizations | 48 | 93 |
| Average Patient Age | 60.8 yrs | 46.4 yrs |
| % Female Patients | 61.1% | 47.6% |
| FDA Approval Date | Jun 11, 2024 | Nov 15, 2024 |
| Manufacturer | E.R. Squibb & Sons, L.L.C. | Syndax Pharmaceuticals, Inc. |
| Route | ORAL | ORAL |
| Marketing Status | Prescription | Prescription |